Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
07:42pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
Why Regeneron Wasn't a Healthy Stock Today
10:30pm, Thursday, 02'nd Jun 2022 The Motley Fool
The company is forking over $900 million in an upfront payment to fully own a cancer drug.
Regeneron to buy Sanofi's cancer drug in $1B deal
06:36pm, Thursday, 02'nd Jun 2022
Regeneron CEO Leonard Schleifer on the decision to spend $1.1B to buy Sanofi's cancer drug portfolio. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman and Dan Nathan.
Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug
03:24pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.
Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug
12:49pm, Thursday, 02'nd Jun 2022
The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
07:50am, Thursday, 02'nd Jun 2022
Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collabora
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
06:39pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
06:22pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
03:48pm, Wednesday, 01'st Jun 2022
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II
12:47pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of ca
FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designation
08:40am, Wednesday, 01'st Jun 2022
Sanofi SNY, -3.45% SAN, +1.17% said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitr
Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag
02:16pm, Tuesday, 31'st May 2022 Zacks Investment Research
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
12:04pm, Tuesday, 31'st May 2022
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) f
Sanofi Ordered to Delay Trial for OTC Cialis. The Stock Falls.
11:03am, Tuesday, 31'st May 2022
The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.
3 Unstoppable Stocks That Are Higher Than Before the Market Correction
03:45pm, Friday, 27'th May 2022 The Motley Fool
Market downturns don't affect stocks equally.
